EU regulator recognises link between AstraZeneca vaccine and cases of thrombosis

The European Medicines Agency (EMA) has concluded that the likelihood of blood clots following vaccination with a drug from British-Swedish company AstraZeneca should be listed as a side effect

“The EMA urges healthcare professionals and vaccinated people to remain aware of the possibility of very rare cases of thrombosis within two weeks of vaccination”, –  the EMA said.

However, the European regulator argues that the benefits of using the vaccine continue to outweigh the risks. At present, experts have yet to find out exactly what causes blood clots.

“Specific risk factors such as age, gender or medical history cannot be confirmed due to the fact that rare adverse events have been observed in men and women at all ages”, –  said EMA head Emer Cook.

Previously, a number of countries had suspended vaccination with the UK-Swedish company AstraZeneca’s drug as a precautionary measure because of numerous reports of blood clots following vaccination.

Comments:

comments powered by HyperComments